Virax Biolabs Group Limited
VRAXNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $644.10K
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.17$13.34
- Volume (live)
- -
- Avg. volume (3M)
- 145.78K
Virax Biolabs Group Limited (VRAX) Analyst Forecast
Analyst consensus ratings, 12-month price targets, and expert recommendations for Virax Biolabs Group Limited stock.
No Analyst Ratings Available
There are currently no analyst ratings available for VRAX in the last 90 days.
Analyst ratings will appear here once they become available from our data sources.
Frequently Asked Questions
Do analysts cover VRAX?
No analyst ratings for VRAX were published in the last 90 days, so there is no current consensus rating or price target.
What do analyst ratings mean?
Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.
What is a price target?
A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.